Akums Expands Its Reach in European and UK Markets with New Certifications
As India's population surpasses 1.46 billion, Akums plays a crucial role in supplying nearly 10% of the country's total medicine consumption by volume, establishing itself as a key player in the national pharmaceutical landscape.
This expansion into the UK market is anchored by the company's recent achievement in gaining the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for Rivaroxaban, an anticoagulant. This approval signifies Akums' direct entry into a crucial segment of the UK pharmaceutical landscape, which has an estimated market value of approximately USD 2.6 billion.
Mr. Sandeep Jain, the Managing Director of Akums, highlighted the significance of these moves, stating, "Our manufacturing strength, regulatory discipline, and development capabilities allow us to enter regulated markets with confidence. This is a calibrated yet ambitious global expansion."
Moreover, Akums has constructed an integrated, innovation-driven Research and Development ecosystem that supports a portfolio of over 20,000 Stock Keeping Units (SKUs). The company boasts four advanced R&D centers and expertise across more than 60 different dosage forms, along with capabilities that span complex injectables and unique drug delivery systems.
Akums currently caters to over 1,500 clients worldwide and operates 14 state-of-the-art manufacturing plants, which comprise 12 formulation facilities and two active pharmaceutical ingredient (API) plants. With a collective production capacity exceeding 50 billion units annually, Akums is well-positioned to meet the demands of regulated global markets.
The recent certifications not only affirm Akums' commitment to quality but also underscore the company’s goal of being recognized as a household name across European and UK markets. With its strong foundation in compliance and credibility in India, Akums aims to replicate its domestic success on an international stage, forging lasting partnerships that will help enhance its global reach and impact in the pharmaceutical sector.
In conclusion, as Akums progresses with its expansion strategy, the company is set to play a significant role in meeting the pharmaceutical needs of Europe and the UK. With its advanced manufacturing capabilities and robust R&D initiatives, Akums is on its way to becoming a pivotal resource in the global pharmaceutical marketplace.
This expansion into the UK market is anchored by the company's recent achievement in gaining the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for Rivaroxaban, an anticoagulant. This approval signifies Akums' direct entry into a crucial segment of the UK pharmaceutical landscape, which has an estimated market value of approximately USD 2.6 billion.
Mr. Sandeep Jain, the Managing Director of Akums, highlighted the significance of these moves, stating, "Our manufacturing strength, regulatory discipline, and development capabilities allow us to enter regulated markets with confidence. This is a calibrated yet ambitious global expansion."
Moreover, Akums has constructed an integrated, innovation-driven Research and Development ecosystem that supports a portfolio of over 20,000 Stock Keeping Units (SKUs). The company boasts four advanced R&D centers and expertise across more than 60 different dosage forms, along with capabilities that span complex injectables and unique drug delivery systems.
Akums currently caters to over 1,500 clients worldwide and operates 14 state-of-the-art manufacturing plants, which comprise 12 formulation facilities and two active pharmaceutical ingredient (API) plants. With a collective production capacity exceeding 50 billion units annually, Akums is well-positioned to meet the demands of regulated global markets.
The recent certifications not only affirm Akums' commitment to quality but also underscore the company’s goal of being recognized as a household name across European and UK markets. With its strong foundation in compliance and credibility in India, Akums aims to replicate its domestic success on an international stage, forging lasting partnerships that will help enhance its global reach and impact in the pharmaceutical sector.
In conclusion, as Akums progresses with its expansion strategy, the company is set to play a significant role in meeting the pharmaceutical needs of Europe and the UK. With its advanced manufacturing capabilities and robust R&D initiatives, Akums is on its way to becoming a pivotal resource in the global pharmaceutical marketplace.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.